---
layout: post
title: "Review Terapi Bisfosfonat pada Pasien Kanker Payudara, Berapa Lamakah Diberikan?"
author: "NGAA Manik Yuniawaty Wetan, Hendry Irawan"
description: "Tujuan Untuk mengetahui efektivitas efek samping serta durasi yang optimal dalam pemberian bisfosfonat pada pasien kanker payudara Metode Pencarian komprehensif dila"
categories: jbn
canonical_url: https://jurnal.harianregional.com/jbn/id-95666
comments: true
citation_abstract_html_url: "https://jurnal.harianregional.com/jbn/id-95666"
citation_pdf_url: "https://jurnal.harianregional.com/jbn/full-95666"
tags:

---

## Authors:
NGAA Manik Yuniawaty Wetan, Hendry Irawan

## Abstract:
"Tujuan: Untuk mengetahui efektivitas, efek samping serta durasi yang optimal dalam pemberian bisfosfonat pada pasien kanker payudara. Metode: Pencarian komprehensif dilakukan pada database PubMed, Science Direct, dan CENTRAL dari tahun 2012 hingga 2022 yang dilakukan selama 10 tahun. Hasil: Tinjauan saat ini, yang termasuk tiga studi randomized controlled trials, yang melibatkan 7.162 kasus kanker payudara, menilai efek bisfosfonat pada risiko kanker payudara serta durasi penggunaan bisfosfonat. Ditemukan adanya pengurangan risiko kanker payudara dengan paparan bisfosfonat. Penggunaan bisfosfonat jangka pendek (&lt;1 tahun) tidak menyebabkan perubahan yang signifikan, sementara penurunan risiko kanker payudara yang signifikan sebesar 26% tercatat dengan penggunaan jangka panjang (&gt;1 tahun). Efek perlindungan bisfosfonat ditunjukkan pada kanker payudara kontralateral. Simpulan: Tinjauan ini menunjukkan bahwa penggunaan bisfosfonat dikaitkan dengan penurunan risiko payudara kanker, termasuk kanker payudara kontralateral. Dibandingkan dengan jenis bisfosfonat lainnya, hanya etidronat yang menunjukkan signifikansi hubungan terbalik. Selain itu, penggunaan bisfosfonat jangka panjang (&gt;1 tahun) lebih signifikan dalam mengecilkan risiko kanker payudara."

### Keywords
*Keyword Not Available*

### Downloads:
Download data is not yet available.

{% include adsense.html %}
## References
- 1.	Black DM, Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med. 2016;374:254-62.
- 2.	Van Acker HH, Anguille S, Willemen Y, dkk. Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials. Pharmacol & Ther. 2016;158:24-40.
- 3.	Fournier A, Mesrine S, Gelot A, dkk. Use of Bisphosphonates and Risk of Breast Cancer in a French Cohort of Postmenopausal Women. J Clin Oncol. 2017;35:3230-39.
- 4.	Ou YJ, Chiu HF, Wong YH, dkk. Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2017;26:1286-95.
- 5.	Hue TF, Cummings SR, Cauley JA, dkk. Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Intern Med. 2014;174:1550-7.
- 6.	Gralow JR, Barlow WE, Paterson AHG, dkk. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. J Natl Cancer Inst. 2020;112:698-707.
- 7.	Coleman R, Cameron D, Dodwell D, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol. 2014;15:997-1006.
- 8.	Perrone F, De Laurentiis M, De Placido S, dkk. Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. Eur J Cancer. 2019;118:178-86.
- 9.	Zhang XS, Zhang YM, Li B, dkk. Risk reduction of endometrial and ovarian cancer after bisphosphonates use: A meta-analysis. Gynecol Oncol. 2018;150:509-14.
- 10.	Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353-61.
- 11.	Amoroso V, Petrelli F, Pedersini R, dkk. Adjuvant bisphosphonates in patients with breast cancer: does the potency matter? Futur Oncol. 2015;11:2853-6.
- 12.	Francis PA, Pagani O, Fleming GF, dkk. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018;379:122-37.
- 13.	Coleman RE, Finkelstein D, Barrios C, dkk. Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study. J Clin Oncol. 2018;36:501.
- 14.	Pan H, Gray R, Braybrooke J, dkk. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017;377:1836-46.
- 15.	Gnant M, Pfeiler G, Steger GG, dkk. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:339-51.
- 16.	Coleman R, Hall A, Albanell J, dkk. Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. Lancet Oncol. 2017;18:1543-52.

### PDF:

{% include adsense1.html %}

<https://jurnal.harianregional.com/jbn/full-95666>

{% include adsense2.html %}

### Published
2023-01-31

### How To Cite
WETAN, NGAA Manik Yuniawaty; IRAWAN, Hendry.  Review Terapi Bisfosfonat pada Pasien Kanker Payudara, Berapa Lamakah Diberikan?.JBN (Jurnal Bedah Nasional), [S.l.], v. 7, n. 1, p. 30-37, jan. 2023. ISSN 2548-981X. Available at: <https://jurnal.harianregional.com/jbn/id-95666>. Date accessed: {{ site.time | date: "%d %b. %Y" }}. doi:https://doi.org/10.24843/JBN.2023.v07.i01.p05.

## Citation Format
ABNT, APA, BibTeX, CBE, EndNote - EndNote format (Macintosh & Windows), MLA, ProCite - RIS format (Macintosh & Windows), RefWorks, Reference Manager - RIS format (Windows only), Turabian

### Issue
Vol 7 No 1 (2023): JBN (Jurnal Bedah Nasional)

### Section 
**Articles**

### Copyright 
{% include inarticle.html %}
<a href="http://creativecommons.org/licenses/by/4.0/" rel="license"><img src="https://i.creativecommons.org/l/by/4.0/88x31.png" alt="Creative Commons License" /></a>
This work is licensed under aÂ <a href="http://creativecommons.org/licenses/by/4.0/" rel="nofollow">Creative Commons Attribution 4.0 International License</a>

{% include multiplex.html %}
